Here's Why Agenus Inc. Stock Slipped 13.6% in July
Shares of Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company, fell 13.6% in July according to data from S&P Global Market Intelligence. Investors viewed a clinical-trial failure reported by AstraZeneca as a harbinger of sorrow for similar candidates in its own pipeline.
Aside from an adjuvant featured in GlaxoSmithKline's shingles-vaccine candidate, Agenus Inc.'s future hinges on success for new drug candidates that inhibit a cancer cell's ability to exploit the CTLA-4 and PD-1 immune-response checkpoints. This is why the market beat up Agenus when AstraZeneca reported its combination of tremelimumab, which blocks CTLA-4, and Imfinzi, which blocks PD-1, failed to provide a significant survival benefit compared to standard chemotherapy for previously untreated patients with stage-four lung cancer.
Image source: Getty Images.
Source: Fool.com
Agenus Inc. Aktie
Die Agenus Inc. Aktie zieht etwas Aufmerksamkeit auf sich: Mehr Buy- als Sell-Einschätzungen.
Mit einem Community-Kursziel von 37 € für Agenus Inc. wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 0.41 € gesehen.
